1,366 Shares in Medpace Holdings, Inc. $MEDP Purchased by United Capital Financial Advisors LLC

United Capital Financial Advisors LLC purchased a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 1,366 shares of the company’s stock, valued at approximately $723,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Johnson Financial Group Inc. acquired a new stake in shares of Medpace in the second quarter worth approximately $27,000. Elyxium Wealth LLC acquired a new position in Medpace during the fourth quarter worth approximately $30,000. Jones Financial Companies Lllp acquired a new position in Medpace during the second quarter worth approximately $30,000. Allied Private Wealth LLC purchased a new position in Medpace during the second quarter worth approximately $31,000. Finally, Kilter Group LLC purchased a new position in Medpace during the second quarter worth approximately $31,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Analysts Set New Price Targets

MEDP has been the subject of several research reports. Truist Financial boosted their price objective on shares of Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Jefferies Financial Group cut Medpace from a “buy” rating to a “hold” rating and lifted their target price for the company from $490.00 to $515.00 in a report on Tuesday, July 7th. Robert W. Baird boosted their price target on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a research report on Friday, July 24th. Barclays set a $600.00 price target on Medpace in a research note on Thursday, July 23rd. Finally, TD Cowen raised their price objective on Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a report on Friday, July 24th. Three research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $584.18.

Insider Buying and Selling

In other news, VP Susan E. Burwig sold 7,500 shares of the company’s stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total value of $4,500,000.00. Following the completion of the sale, the vice president owned 62,984 shares of the company’s stock, valued at $37,790,400. This represents a 10.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Fred B. Davenport, Jr. sold 7,283 shares of the stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $606.15, for a total value of $4,414,590.45. Following the completion of the sale, the director owned 3,798 shares of the company’s stock, valued at approximately $2,302,157.70. This trade represents a 65.73% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 133,821 shares of company stock valued at $81,748,135. 20.50% of the stock is owned by company insiders.

Medpace Price Performance

Medpace stock opened at $600.65 on Monday. The firm has a fifty day moving average of $565.33 and a 200-day moving average of $494.30. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $677.90. The firm has a market capitalization of $16.76 billion, a P/E ratio of 35.21, a PEG ratio of 2.68 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last posted its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. During the same quarter in the previous year, the business posted $3.10 EPS. The business’s quarterly revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, research analysts expect that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.